中华心脏与心律电子杂志 ›› 2018, Vol. 06 ›› Issue (03) : 149 -151. doi: 10.3877/cma.j.issn.2095-6568.2018.03.007 × 扫一扫
所属专题： 文献；
论著
收稿日期:
出版日期:
通信作者:
Zhitao Zhang1, Lei Zhang1, Ke Hu1()
Received:
Published:
Corresponding author:
张志涛, 张蕾, 胡珂. 丹参酮ⅡA磺酸钠注射液联合艾司洛尔治疗不稳定型心绞痛的效果观察[J]. 中华心脏与心律电子杂志, 2018, 06(03): 149-151.
Zhitao Zhang, Lei Zhang, Ke Hu. Effect of tanshinone ⅡA sodium sulfonate injection combined with esmolol in the treatment of unstable angina pectoris[J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2018, 06(03): 149-151.
探讨丹参酮ⅡA磺酸钠注射液联合艾司洛尔治疗不稳定型心绞痛的临床效果。
选取济南市长清区人民医院2017年5月至2018年3月收治的196例不稳定型心绞痛患者，依照治疗方案分为观察组(98例)和对照组(98例)。对照组在常规治疗基础上接受艾司洛尔治疗，观察组在常规治疗基础上接受丹参酮ⅡA磺酸钠注射液联合艾司洛尔治疗。观察对比两组患者临床治疗效果、心绞痛发作频率、心绞痛持续时间及心肌梗死发生率。
对照组治疗总有效率为69.39%(68/98)，观察组治疗总有效率为93.85%(91/98)，差异有统计学意义(P<0.05)。治疗14 d后，两组患者心绞痛发作频率、持续时间均较治疗前改善，观察组心绞痛发作频率较对照组低，持续时间较对照组短，差异有统计学意义(P<0.05)。治疗14 d后，两组患者hs－CRP、BNP、MMP－9水平较治疗前降低，观察组hs－CRP、BNP、MMP－9水平较对照组低，差异有统计学意义(P<0.05)。观察组患者无心肌梗死发生，对照组心肌梗死11例(11.22%)，组间心肌梗死发生率差异有统计学意义(P<0.05)。
丹参酮ⅡA磺酸钠注射液联合艾司洛尔可改善不稳定型心绞痛症状，降低血清hs－CRP、BNP、MMP－9水平，疗效显著。
To explore the clinical effect of sodium tanshinone ⅡA sulfonate injection combined with esmolol in the treatment of unstable angina pectoris.
A total of 196 patients with unstable angina pectoris admitted to Changqing District People's Hospital of Jinan from May 2017 to March 2018 were divided into observation group (98 cases) and control group (98 cases) according to the treatment plans. The control group received esmolol treatment on the basis of routine treatment, while the observation group received tanshinone II A sulfonate sodium injection combined with esmolol treatment on the basis of routine treatment. The clinical effect, frequency of angina attack, duration of angina pectoris and incidence of myocardial infarction were observed and compared between the two groups.
The total effective rate was 69.39% (68/98) in the control group and 93.85% (91/98) in the observation group, and the difference was statistically significant (P<0.05). After 14 days of treatment, the frequency and duration of angina pectoris in both groups were improved compared with those before treatment. The frequency and duration of angina pectoris in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05). After 14 days of treatment, the levels of hs-CRP, BNP and MMP-9 in the two groups were lower than those before treatment, while the levels of hs-CRP, BNP and MMP-9 in the observation group were lower than those in the control group (P<0.05). There was no myocardial infarction in the observation group and 11 cases (11.22%) in the control group. There was a significant difference in the incidence of myocardial infarction between two groups (P<0.05).
Sodium tanshinone ⅡA sulfonate injection combined with esmolol can improve the symptoms of unstable angina pectoris and reduce the levels of hs-CRP, BNP and MMP-9 in serum.